Benzinga  Dec 11  Comment 
In a report published Thursday, UBS Securities analyst Andrew Peters reiterated a Buy rating on BioMarin Pharmaceutical (NASDAQ: BMRN), and raised the price target from $87.00 to $112.00. In the report, UBS Securities noted, “We see BioMarin...
Benzinga  Dec 10  Comment 
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Food and Drug Administration (FDA) has granted orphan drug designation for BMN 250, a novel fusion of alpha-N-acetyglucosaminidase (NAGLU) with a peptide derived from...
Motley Fool  Nov 25  Comment 
BioMarin's acquisition of Prosensa puts it in direct competition with Sarepta.
Benzinga  Nov 24  Comment 
Following the market opening Monday, the Dow traded up 0.07 percent to 17,822.01 while the NASDAQ gained 0.53 percent to 4,738.13. The S&P also rose, gaining 0.20 percent to 2,067.54. Leading and Lagging Sectors In trading on Monday,...
Benzinga  Nov 24  Comment 
Prosensa Holding N.V. (NASDAQ: RNA) shares jumped 63.02% to reach a new 52-week high of $18.65 after BioMarin Pharmaceutical (NASDAQ: BMRN) announced its plans to acquire Prosensa for $17.75 per share. CDW (NYSE: CDW) shares touched a new...
Benzinga  Nov 24  Comment 
Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) are in play on Monday amid consolidation announcements within the sector. On Monday, BioMarin Pharmaceutical Inc. announced the company will acquire Prosensa Holding NV for roughly $680...
Benzinga  Nov 24  Comment 
Prosensa Holding NV (NASDAQ: RNA) shares jumped 62.15% to $18.55 in pre-market trading after BioMarin Pharmaceutical (NASDAQ: BMRN) announced its plans to acquire Prosensa for $17.75 per share. Cimatron (NASDAQ: CIMT) shares surged 43.56% to...
Wall Street Journal  Nov 24  Comment 
BioMarin Pharmaceutical said it agreed to acquire Prosensa Holding NV, a bet that regulators will approve Prosensa’s lead product candidate for a rare form of muscular dystrophy.
Market Intelligence Center  Nov 12  Comment 
BioMarin Pharmaceutical (BMRN) traded between $85.77 and $87.50 before closing at $86.12 Tuesday and presents some attractive trading opportunities today. MarketIntelligenceCenter.com’s patented algorithms selected a Jan. '15 $85.00 covered call...


BioMarin Pharmaceutical Inc. (BMRN), a developer of enzyme-related therapies (ERT), co-markets Aldurazyme with Genzyme Corporation (GENZ) for the treatment of MPS-I (mucopolysaccharidosis). MPS-I is a rare genetic enzyme deficiency disorder, afflicting roughly 3,000 people worldwide, caused by the lack of a specific enzyme involved in lysosomal storage. More common names for mucopolysaccharidosis are Hurler's Syndrome, Hurler-Scheie, and Scheie's Disease. The company's other developed product, Naglazyme, for MPS-VI, recently entered the market. MPS-VI is also a rare genetic enzyme deficiency disorder, with an estimated 1,100 people suffering from it worldwide. The company's third lead drug, Kuvan, received FDA approval for the treatment of PKU in December 2007. With the recent launch of Kuvan, the company now has three products on the market. The company also receives royalties and license revenue on sales of the Orapred franchise from Alliant Pharmaceuticals. In 2004, the company acquired Orapred, a grape-flavored oral corticosteroid liquid for the treatment of severe asthma in children and subsequently licensed the franchise to Alliant Pharmaceuticals in March 2006. BioMarin, headquartered in Novato, CA, employs roughly 300 people.

Business Overview

Business & Financial Metrics

In 2009, BMRN incurred a net loss of $488 thousand on revenues of $324.7 million. This represents a real turnaround from 2008, when the company earned $30.8 million on $296.5 million in revenues.[1]

Geographical Distribution[2]

BioMarin generates the majority of its revenues from sales in Europe.



BioMarin competes with companies like:


  1. BMRN 2009 10-K pg. 36  
  2. 2.0 2.1 BMRN 2009 10-K pg. 16  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki